Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Servier
8 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Corporate Social Responsibility
Giving Structure to a Long-Term CSR Strategy
PAP-Q4-19-CL-030
Containment
Meeting the Need for Higher Containment
PAP-Q3-19-CL-025
Serialization Update
Revisiting the Global Serialization Landscape
PAP-Q2-2019-CL-030
Expansion
Servier Cuts Ribbon on New Boston Headquarters
PR-M05-19-NI-037
Outsourcing
Aligning the Outsourcing Relationship
PAP-Q1-2019-CL-006
Collaboration
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
PR-M03-19-NI-057
DCAT '19
Highly Potent API and Sterile Capabilities Key to DCAT Week ‘19 Company Announcements
PAO-M03-19-NI-024
Collaboration
Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
PR-M02-19-NI-052
